Banque Cantonale Vaudoise Trims Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Banque Cantonale Vaudoise lessened its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,260 shares of the company’s stock after selling 4,493 shares during the period. Banque Cantonale Vaudoise’s holdings in Teva Pharmaceutical Industries were worth $202,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 92.3% during the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock worth $46,000 after acquiring an additional 2,180 shares during the period. Psagot Value Holdings Ltd. Israel bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $57,000. Newbridge Financial Services Group Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $82,000. Desjardins Global Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 15.2% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after purchasing an additional 1,070 shares in the last quarter. Finally, Schechter Investment Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $117,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 2.8 %

TEVA stock opened at $16.49 on Tuesday. Teva Pharmaceutical Industries Limited has a 1 year low of $7.42 and a 1 year high of $17.69. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.61 and a current ratio of 0.89. The stock’s fifty day moving average price is $15.72 and its 200-day moving average price is $13.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. The firm had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.3 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on TEVA. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target on the stock in a research report on Friday, March 8th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 20th. Barclays increased their target price on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. Bank of America increased their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $20.00 target price (up from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.88.

Insider Buying and Selling

In related news, insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $16.74, for a total value of $254,766.06. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the sale, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The disclosure for this sale can be found here. In the last three months, insiders have sold 549,719 shares of company stock valued at $9,353,736. 0.55% of the stock is owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.